retatrutide triple agonist glp-1 gip glucagon phase 3 2025 The Science Behind Retatrutide: A New Hope for Obesity and Diabetes – Prime Lab Peptides Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide

Devon Gholam, VP science and innovation at ingredient incubator and innovation firm Step Change Innovations, says she has noticed that some companies marketing ingredients that impact glucose control and weight management are finally having a moment in the Ozempic era, as consumers reading about GLP-1 drugs start looking for natural alternatives

Understanding these variables helps contextualise any changes observed during treatment and prevents unnecessary anxiety

Research on GLP-1 therapy discontinuation suggests that certain metabolic improvements show partial persistence even after weight regain

In clinical research, participants taking tirzepatide had average systolic blood pressure reductions of about 7.4 to 10.6 mm Hg after 36 weeks